Financial research concept

Loss of Exclusivity (LOE): When a Drug Faces New Generic or Biosimilar Competition

Loss of exclusivity is the point when a branded drug's commercial protection weakens enough for generic or biosimilar competition to enter or become economically relevant.

By Lee BaileyPublished Sep 21, 2026

Research context

See what supports this page, how current it is, and where comparable or historical context is available.

Research date: Sep 21, 2026Use the dated article and cited sources for the definition, examples, and stated limitations.
Operating-model context: 16 connected conceptsPart of the reviewed Biopharma Development and Commercialization; issuer definitions remain distinct where disclosed.
Company examples: 1 reviewed companyRelationships reflect supported examples, not a normalized cross-company KPI ranking.

Why LOE matters
Patent expiry versus LOE
Part of the Biopharma Development and Commercialization
See It in Company Research
Continue Research

Loss of exclusivity, or LOE, describes the erosion or end of the legal and regulatory protections that shield a branded pharmaceutical product from generic or biosimilar competition.

Why LOE matters

LOE can lead to:

lower price;
market-share erosion;
contracting pressure;
revenue decline; and
changes in promotional spending.

The impact varies by product type, market structure, patents, settlements, and competitor timing.

Patent expiry versus LOE

A patent can expire without immediate competition if other protections remain.

Conversely, settlements, patent challenges, or regulatory events can change the practical competition date.

AbbVie explicitly warns that expiration or loss of patent protection and licenses, including loss of exclusivity, can adversely affect revenue and operating earnings.

Source:

AbbVie 2025 Form 10-K

LOE is a commercial-protection event, not merely a single patent expiration date.

Part of the Biopharma Development and Commercialization

Connect clinical-trial evidence, FDA application and expedited pathways, collaboration economics, gross-to-net commercialization, and loss-of-exclusivity risk to understand drug-development businesses.

Browse the full operating model in Company Analysis →

Where this concept fits

Commercialization, partnerships, and exclusivityCurrent relationship
Gross-to-net adjustments bridge gross product demand to recognized revenue, royalties and milestones describe partner economics, and patent expiry plus loss of exclusivity frame when legal protection may translate into competitive revenue erosion.
Biopharma Gross-to-Net Adjustment Biopharma Milestone Payments Biopharma Royalty RevenueLoss of ExclusivityCurrent conceptBiopharma Patent Expiry
Clinical evidence and execution
Trial phase frames development maturity, enrollment affects execution timing, primary and secondary endpoints define the prespecified evidence hierarchy, and a readout converts that study design into new evidence for investors to interpret.
Clinical Trial Phase Clinical Trial Readout Patient Enrollment Primary Endpoint Secondary Endpoint
FDA pathway and review milestones
NDA and BLA submissions begin formal marketing review for drugs and biologics, PDUFA dates frame target action timing, and accelerated approval, Breakthrough Therapy, and Orphan Drug designations describe distinct regulatory pathways or incentives rather than approval outcomes.
Accelerated Approval Biologics License Application Breakthrough Therapy Designation New Drug Application Orphan Drug Designation PDUFA Date

See It in Company Research

These companies are examples of how the concept is reported or discussed in public filings. Definitions can differ by issuer; these links open company research rather than a normalized metric comparison.

ABBVOpen operating-model research →2 of 16 reviewed concepts in Biopharma Development and CommercializationCommercialization, partnerships, and exclusivity2 of 5 bridge concepts supportedContinue through this bridge:Biopharma Patent Expiry

Explore other companies in this operating model

These companies are linked to at least two other reviewed concepts in the same operating model, but are not currently linked to this concept. This is broader research navigation, not evidence that the company reports an equivalent metric.

Continue Research

Continue from the concept into the Grizzly Bulls research surface that best matches the next question. These links are research continuations, not recommendations or required steps.

Compare stocks

Compare biopharma stocks

Continue into stock comparison for pipeline stage, regulatory milestones, commercialization economics, concentration, and valuation context.

Continue research

Explore more topics in the Financial Research Encyclopedia.